Wolfe Research analyst Kalpit Patel downgraded Corcept Therapeutics (CORT) to Underperform from Peer Perform with a $30 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Why Is Corcept Therapeutics Stock (CORT) Down Today?
- Morning Movers: Nvidia up as report points to strong demand in China
- Corcept Therapeutics down 40% to $42.16 after receiving CRL for relacorilant
- FDA says it needs additional evidence of effectiveness for Corcept relacorilant
- Corcept Therapeutics to resume trading at 8:20 am ET